Abstract: As the human lifespan continues to rise, the number of elderly patients with interstitial lung disease (ILD) has never been higher. Idiopathic pulmonary fibrosis is the most common ILD among older patients, but ILD related to autoimmune disease and hypersensitivity pneumonitis are also important diseases in this age group. Usual interstitial pneumonia is the histopathologic pattern of IPF; mitochondrial dysfunction, oxidative stress from telomere damage, and endoplasmic reticular stress from the unfolded protein response are the aging processes implicated in alveolar epithelial cell injury and downstream aberrant fibroblast activity. Driven by a variety of connective tissue and musculoskeletal changes, pulmonary fitness declines with aging, which is reflected in lower measures of spirometry and diffusion capacity. Frailty and increased susceptibility to infection compound these effects. For these reasons, along with polypharmacy concerns, old age can complicate the management of ILD. That said, most older patients tolerate treatment, and advanced age (above 80 y) alone is not a contraindication for immunosuppressive or antifibrotic therapies. In addition, lung transplantation can be beneficial in carefully selected older patients. Finally, it is not clear whether subclinical interstitial abnormalities, observed on chest imaging in a sizeable number of older patients, represent an early phase of ILD. While currently available data are reassuring, more research is needed to better understand outcomes for these patients.
I
nterstitial lung disease (ILD) encompasses a spectrum of noninfectious inflammatory and fibrotic parenchymal injuries. Idiopathic pulmonary fibrosis (IPF), connective tissue disease ILD (CTD-ILD), sarcoidosis, and hypersensitivity pneumonitis (HP) are the most common ILDs in mixed aged cohorts. Asbestosis, chronic beryllium disease, pleuroparenchymal fibroelastosis, and idiopathic nonspecific interstitial pneumonia are less common but still well represented in specialty clinics. In addition, the recognition of unclassifiable ILD, marked by nonspecific clinical features or inconclusive testing results, is on the rise. ILD morbidity ranges from mild to severe, and many patients with ILD die prematurely. Outcomes are generally worse for fibrotic ILD, with IPF being noted as a particularly aggressive and fatal disease.
Uncommon in pediatric populations, ILD considered collectively is largely a disease of adulthood. Some ILDs, such as IPF and asbestosis, are nearly exclusively diseases of the elderly. Becoming elderly is a process and does not occur at a single point in time. However, defining elderly by a discrete age threshold attempts to capture, however imperfectly, the shifts in physiological function associated with biological aging. For the purposes of research and clinical practice, elderly is typically defined as age 60 to 65. Biological clocks mediating declines in immune system function, organ function, tissue homeostasis, and regenerative capacity-declines that generally begin in earnest in the fifth to sixth decades of life-are not altered by increased life expectancies. 1 In other words, people are living longer in aged bodies. This has particularly important implications for the management of ILD, which can be a taxing disease even for young and optimally fit patients. These implications are the focus of this review, which considers the normal changes in lung function with aging, the effect of age on ILD pathobiology in the case of usual interstitial pneumonia (UIP), and ILD management in the older patient.
THE AGING LUNG
A multitude of normal changes (Table 1) and acquired insults affect lung reserve in elderly persons. Some of these, including altered immune function and aspiration risk, may directly contribute to the risk and pathophysiology of ILD. Others are less related, but nonetheless affect tolerance of ILD, and as such are considered here.
Loss of lung function is a normal aging process. After peaking in the second to third decade, lung function undergoes a steady, albeit nonlinear decline with age. It is the main contributor to a decline in airflow. Loss of elastic recoil also compromises airway tethering, leading to dynamic collapse of small airways and air trapping, which limits exercise capacity. At the same time that lung tissue loses elastic recoil, the chest wall becomes less compliant with age. These changes impose increased workloads on expiration and inspiration, respectively. Compounding this burden, respiratory muscles generally weaken with age. Gas exchange is also affected by aging processes; changes in ventilation/perfusion matching due to altered microcirculation mediate widening of the alveolar-arterial gradient and a reduction in diffusion capacity with age.
Alterations in pulmonary mechanics and gas exchange are reflected a decline in the absolute values of pulmonary function 
Aging-related Change
Effect of This Change testing. 2 Age-related reductions in the forced expiratory volume in 1 second (FEV1) are often more pronounced than reductions in the forced vital capacity (FVC). This is associated with a slow but steady decline in the FEV1/FVC ratio. Aging seems to move lung function in the direction of obstructive physiology, particularly when obstruction is defined by a fixed FEV1/FVC ratio. Therefore, relying on an absolute cut-off value for this ratio risks misclassifying normal physiological changes as pathologic in the elderly. 3 Truly abnormal airflow limitation in this cohort is more accurately detected by utilizing the lower limit of normal when evaluating the FEV1/FVC ratio. 4 Elevations in the residual volume indicate air trapping. 2 The total lung capacity is less affected by aging due to balanced losses of inward elastic recoil and chest wall outward spring. 5 Declining values in the diffusion limitation of carbon monoxide reflect a loss of diffusion capacity with age. However, identifying a borderline abnormal diffusion capacity in individuals of advanced old age (above 80 y old) can be difficult, as data on normal predicted values are limited. Although a reduced diffusion limitation of carbon monoxide may be a sensitive marker for early ILD, 6 the findings of a restriction pattern is the most reliable pulmonary function finding for ILD. Elderly patients, generally, are adequately able to perform pulmonary function testing, although healthy elderly cohorts have a wider distribution of test results compared with nonelderly cohorts. 7 This further supports the utilization of the lower limit of normal in the interpretation of pulmonary function testing in older patients. Finally, waning respiratory muscle strength is reflected in lower measurements of maximal inspiratory pressure and maximum voluntary ventilation. However, robust predicted ranges for normal respiratory muscle strength are largely lacking in the elderly, and clinical judgement is required in the interpretation of muscle strength testing results. Comorbidities associated with aging negatively affect pulmonary fitness, and afford less reserve for a superimposed ILD. Chronic obstructive pulmonary disease and cardiovascular disease, for example, are prevalent and may contribute to dyspnea, hypoxemia, and exertional limitation among patients with ILD. Obstructive sleep apnea is also common, and perhaps even exceptionally common, among patients with IPF, and may contribute to nocturnal hypoxemia. 8, 9 While a survival benefit for treating obstructive sleep apnea in patients with IPF has not been demonstrated, treatment is associated with increased quality of life measures. 10 Pulmonary artery pressures increase with age, and, in a population study, this increase was associated with higher mortality. 11, 12 However, in patients with IPF, age has not been found to be a clear risk factor for pulmonary hypertension. Among patients with ILD, development of pulmonary hypertension, regardless of age, is associated with reduced functional capacity and worse survival. Finally, the risk of pulmonary embolism increases with age, although the clinical significance of incidental, subsegmental pulmonary emboli in otherwise healthy individuals is unclear. 13 The frequency of pulmonary emboli is higher in patients with IPF compared with the background population; while older age was associated with thromboembolic disease in women, an age-association in men with IPF was not detected, suggesting that thromboembolic risk from IPF outweighs that from age. 14 
THE AGING IMMUNE SYSTEM
A variety of age-related impairments in the immune system have been identified. Progressive thymic involution, which begins in early adulthood, is associated with a dwindling population of naïve circulating T cells, resulting in a repertoire increasingly comprised of memory cells. In addition, T helper (Th) cell polarization skews from Th1 to Th2 with age. Combined, these changes are associated with decreased cellmediated immune responses in older age. The fate of regulatory T (Treg) cell function with aging has been insufficiently characterized, but early studies demonstrate stable numbers of circulating Treg cells, albeit with a contracted repertoire similar to that observed for the pool of T effector cells. 15 While still unproven, a role for preserved Treg cell functionality in the face of declining effector function has been suggested to contribute to higher rates of cancer with aging. Conversely, impaired Treg cell function has been invoked to account for the development of autoimmune disease in older age. More work is needed to clarify the relationship between Treg cell function, age, and illness. B-cell populations also seem to dwindle with age, and the capacity for antibody production to novel antigens diminishes. 16 Changes in innate immune function have been observed in older cohorts. However, compared with those of the adaptive immune system, these impairments and their clinical relevance are less clearly defined. Most studies investigating the effect of aging on immune function have focused on systemic inflammatory responses. 17 Data on immune function specifically in the lung compartment, are limited, although a proinflammatory milieu has been identified in cohorts of healthy elderly subjects. 18, 19 Age-related alterations in immune function have an impact on pulmonary health. Perhaps of most concern, declining immune function in the elderly is associated with increased risk of pulmonary infection. Rates of communityacquired pneumonia, postoperative pneumonia, and severe pneumonia are higher among the elderly. 20, 21 While a variety of possible factors contribute to these higher rates-including aspiration related to oropharyngeal dysfunction, compromised nutritional status, and reduced mucociliary clearancealterations in immune function are an additional, independent risk factor for acute pneumonia in the elderly. 19, 22 Advancing age is also associated with increased risk for mycobacterial infections. The development of chronic mycobacterium avium complex infection in immunocompetent patients is strongly associated with aging and, among human immunodeficiency virus-negative patients, rates of reactivation tuberculosis increase with age. 23 Incidence and complication rates of upper respiratory tract viral infections also increase with age. Particularly well publicized for influenza, for which hospitalization rates and death are strongly associated with advanced age, older patients are vulnerable to other respiratory viruses as well. 24, 25 The risk of Haemophilus influenzae increases with age and, following introduction of the H. influenzae serotype b (Hib) vaccine for children, elderly patients now account for the largest proportion of cases of H. influenzae in the United States. 26 For pertussis and respiratory syncytial virus, diseases often associated with pediatric populations, elderly compared with nonelderly adults experience higher rates of hospitalization and death. 25, 27 These rates are not trivial, and, by some estimates, morbidity and mortality are higher for respiratory syncytial virus compared with influenza infection in the elderly. 28 While speculative, the more pronounced decline in cytotoxic CD8 T-cell function over that of CD4 T-cell function may mediate an age-related susceptibility to viral infections. 29 Beyond infection, agerelated immune alterations are associated with increased rates of malignancy. Incident rates for many cancers are highest in the elderly, wherein well over half of all new cancer diagnoses are in patients aged 65 or older. 30 Lung cancer, in particular, is strongly associated with aging, with a median age of diagnosis
INTERSTITIAL LUNG DISEASE IN THE ELDERLY Epidemiology
Incident rates of most ILDs vary by age. IPF is the ILD most strongly associated with aging. Exceedingly rare in young adults, the incidence of IPF steadily increases starting in the sixth decade. 33, 34 Similarly, asbestosis, another UIP pattern disease, occurs nearly exclusively in older individuals. 35 Unclassifiable ILD is particularly common among elderly patients, many of whom have not undergone surgical lung biopsy. In one study of elderly patients with a low biopsy rate, unclassifiable ILD was more common than IPF. 36 Unclassifiable ILD seems to include patients with missed diagnoses of IPF (in patients who have not undergone biopsy but have underlying UIP) and other ILDs, in addition to a subset with truly unclassifiable disease. 37 In a study of patients with ILD without radiographic honeycombing, old age was found to be a very strong predictor of UIP on histopathology; an age cut-off of 70 years was associated with a 95% positive predictive value of finding UIP on histopathology. 38 However, patients with sarcoidosis, CTD-ILD, and difficult to classify disease were excluded from analysis, and the cohort prevalence of HP was low. In another study of elderly patients, various ILD diagnoses were established after histopathologic assessment. 39 While more research is needed, it seems reasonable to conclude that histological UIP/clinical IPF is highly although not exclusively present among older patients with unclassifiable ILD. Beyond IPF and unclassifiable ILD, CTD-ILD and HP, considered in turn below, are the other common ILD subtypes that occur in the elderly. 36 New-onset autoimmune disease occurs across the human lifespan. With the exception of giant cell arteritis, older patients are not at higher risk of developing autoimmune disease, but conversely niether are they protected against it. Rheumatoid arthritis, systemic lupus erythematosus (SLE), systemic sclerosis, Sjögren's syndrome, and polymyositis/dermatomyositis, in descending order of frequency, are the most likely to present in old age. 6, 40 Rheumatoid arthritis is the most common autoimmune disease among elderly patients with CTD-ILD. 6, 40 Up to 1% of the general population is affected by rheumatoid arthritis, and patients diagnosed at a young age are increasingly surviving to older age. In addition, an estimated 30% of cases present late in life. For both younger and older groups with rheumatoid arthritis, ILD is a relatively common complication, occurring in 10% to 30% of patients. In contrast, while SLE is a common autoimmune disease, ILD is an uncommon complication. Higher rates of ILD, however, are observed among patients who are elderly at the time of SLE onset. 41 The relationship between age of onset of autoimmune disease and development of lung involvement is less clear for other CTDs. In contrast, age of ILD onset has been shown to be a strong predictor of survival in CTD-ILD with older age of disease onset associated with higher mortality in CTD-ILD. In one study, this appeared to be an effect of more severe ILD (fibrosis extent, pulmonary function limitation) in older compared to younger patients with CTD-ILD. 42 In CTD-ILD, lung involvement typically is recognized in the setting of an established diagnosis of autoimmune disease. However, ILD may be the presenting manifestation of an autoimmune disease, and all patients with seemingly idiopathic ILD merit ongoing surveillance for autoimmune features. 43 Yet, establishing the diagnosis of autoimmune disease in the older patient can be difficult. One reason is the increased prevalence of nonautoimmune arthritis, fatigue, and esophageal symptoms. [44] [45] [46] In addition, dry mouth and dry eyes, which can occur independent of medication use, are common among the elderly. 47 A separate challenge is that of increased levels of autoantibodies in older age. In one study, 31% of healthy elderly (above 80 y) persons had elevated levels of circulating anti-nuclear antibodies. 48 In a different study, the distribution of rheumatoid factor levels increased with age, although titers tended to be only mildly elevated among patients who clinically remained free of autoimmune disease. 49 Several factors make HP another potentially challenging ILD to diagnose in older patients. Gold standard diagnostic criteria are lacking, and identifying the triggering antigen is often difficult in cases of occult exposure. In addition, features of HP can mimic other ILDs. This may be particularly the case for elderly patients with HP, who are more likely to develop fibrotic disease, including UIP-patterned disease. 50 The overlap of features in fibrotic HP and IPF, and the risk of misdiagnosis, was highlighted in a recent study. Utilizing an aggressive antigen detection assessment, 43% of patients previously diagnosed with IPF ultimately met their study criteria for HP. 51 An accompanying editorial raised important questions about the meaning of these findings, including the possibility that dysregulated immune responses in the setting of an altered epithelial barrier facilitate development of antibodies to exogenous antigens in patients with IPF. 52 Indeed, among those with definitive antibody results, nearly half (10 of 22) of patients with a final diagnosis of IPF tested positive to bird antigens, mold antigens, or both. 51 Whether missed HP is widely prevalent among patients initially diagnosed with IPF remains to be clarified. Regardless, more research is needed to understand the phenotype of new onset fibrotic HP in older age without, in many cases, a clear antecedent history of subacute disease. In the meantime, a detailed exposure query is critical for all patients with ILD. In addition, when the diagnosis is in question, the identification of HP-like inflammatory changes on histopathology, even when superimposed on a background of UIP, is of clinical relevance, as immunosuppression and environmental remediation may be beneficial in these patients. In contrast, the therapeutic role these interventions in patients diagnosed with fibrotic HP with a UIP pattern and limited inflammation on histopathology is unknown.
In contrast to the above diseases, other ILDs account for a small fraction of the total ILD burden among older patients. Rates of new-onset parenchymal sarcoidosis decline with advancing age. 36 While a recent study of predominantly white patients of Northern European background identified an upward shift in the average age of diagnosis of sarcoidosis, the rate of parenchymal involvement was not assessed by age group, and thoracic lymphadenopathy was the most common clinical phenotype overall. 53 In a study specifically evaluating the disease features of late-onset sarcoidosis (diagnosed age 65 y and above), parenchymal involvement was noted in only 32% of cases, and pulmonary function in the elderly cohort was, on average, normal. 54 Therefore, clinically relevant, new-onset parenchymal sarcoidosis still seems to be uncommon among older patients, although the diagnosis should be considered in the setting of compatible clinical features. Other ILDs, including organizing pneumonia (cryptogenic or secondary), lymphocytic interstitial pneumonia, eosinophilic pneumonia, idiopathic nonspecific interstitial pneumonia, and pleuroparenchymal fibroelastosis can occur in older age, but are uncommon causes of elderly ILD, just as they are relatively uncommon causes of ILD in nonelderly adults. [55] [56] [57] [58] [59] Finally, Langerhans cell histiocytosis and respiratory bronchiolitisassociated ILD, both strongly associated with smoking, are distinctly uncommon among the elderly, although they could occur in the setting of increased tobacco exposure in patients of any age. 60 The Role of Age in the Pathophysiology of Interstitial Lung Disease
As UIP occurs nearly exclusively in the elderly, and is the most common ILD pattern in older age, the role of aging in its pathobiology is explored here. The salient histopathologic features of UIP include the following: (1) loss of type I alveolar epithelial cells (AECs) with the expansion of dysfunctional type II AECs; (2) disruption of the basement membrane, with failure to constitute a functional provisional matrix to support normal wound healing; and (3) foci of fibroblasts, which elaborate stiff, nonresolving collagen fibers. Microscopic honeycombing is also a hallmark finding in UIP. 61 Macroscopic honeycombing evident on chest imaging is common, although not necessary to establish the diagnosis of UIP, and may be a late-stage finding related to disease progression (Fig. 1) .
Accounting for the histopathologic findings, events in 2 compartments of the lung mediate the initiation and propagation of UIP (Fig. 2) . AEC injury in the intra-alveolar compartment is largely accepted to be the starting point for UIP. A history of smoking is the most common exposure identified among patients with IPF, although wood and metal dust exposure, latent viral infection of alveolar cells, and gastroesophageal reflux may also have a role in AEC injury. Results of genetic studies have identified the accumulation of defective surfactant (and accompanying endoplasmic reticulum stress) as well as impaired mucociliary clearance (via gain of function MUC5B gene alterations) as other possible endogenous agents of injury. 62, 63 Impaired autophagy amplifies injury mediated by the accumulation of misfolded proteins. 64, 65 Altered surfactant function may also contribute to chronic mechanical injury and reduced alveolar stability in UIP. 66 Potential responses to cellular injury include apoptosis, autophagic cell death, and senescence. While apoptotic cells are readily identified in UIP tissues, this response to injury is not unique to old age. 67 In contrast, senescence is related to aging, and, in UIP, appears to be the main response to injury that drives fibrosis in the subalveolar compartment. 68, 69 Damage to telomeres, particularly vulnerable regions of DNA, and the oxidant products of mitochondrial dysfunction activate an intracellular alarm system, termed DNA damage response (DDR) signaling. This signaling response is a potent inducer of senescence. 70, 71 The loss of protective telomere caps, incurred through replicative telomere shortening or via length-independent oxidant damage, predisposes to telomere damage space. 65, [72] [73] [74] [75] A wear and tear phenomenon, mitochondrial functional loss is normally mitigated by mitophagy, a process to disassemble expiring organelles. Yet mitophagy is often impaired in older age. Age-related damage of mitochondrial DNA can further accentuate mitochondrial dysfunction. These can be self-amplifying events: the release of oxidants from mitochondrial dysfunction contributes to nuclear DNA telomere damage, and the initiation of the DDR signaling program from telomere damage induces mitochondrial production of reactive oxygen species. 76 In this way, once initiated, the program of senescence is difficult to thwart in aged, end-stage cells. The condition of senescence in alveolar cells not only caps regenerative capacity via cell cycle arrest, 77 but also mediates proinflammatory and profibrotic events in the subalveolar compartment. 68, 78 Specifically, the release of bioactive molecules by senescent cells drives fibroblast activation and damage to the extracellular matrix (ECM). 79 Collectively, these changes are termed the senescence-associated secretory phenotype (SASP).
The loss of type I AECs, followed by failed regeneration and the SASP signaling program in type II AECs, sets the stage for progressive fibrosis in the subalveolar compartment. There, fibroblasts elaborate collagen, leading to irreversible fibrosis. These mesenchymal cells, termed myofibroblasts in deference to their contractile properties, are resistant to apoptosis, and matrix deposition is a progressive and often terminal process. Human lung fibroblasts become more profibrotic with aging, and markers of aging are observed in UIP fibroblasts, including cellular senescence, telomere damage, and mitochondrial damage. 80, 81 Age-related changes in TGF-β1 are also associated with aberrant fibroblast activity. 82 While these data are compelling, the role of aging processes (including senescence) in fibroblast dysfunction in UIP has been debated. 80 For example, despite the association of fibroblast senescence with profibrotic activities, a recent editorial raised the question of whether AEC senescence is the main disease-driving event in UIP. 68, 83 In addition, the senescence of fibroblasts stands as an unresolved paradox to the notion that they undergo in situ polyclonal proliferation. 68, 84, 85 Beyond the SASP signaling program and downstream fibroblast dysfunction, other age-related processes may predispose to failed wound healing in UIP. Changes in the unstressed lung ECM, including an increase in profibrotic fibronectin, naturally occur with aging. 86 In conditions of damaged matrix, age-related changes in macrophage function, as well as deficits in neovascularization, growth factor levels, and immune signaling impair repair. 87 In this way, changes in the ECM likely contribute in their own right to progressive fibrosis in UIP. Indeed, decellularized ECM from IPF tissue promoted fibrotic responses from donor fibroblasts. 88 Taken together, aging-related FIGURE 1. Axial image from a computed tomographic scan of an elderly man with symptomatic idiopathic pulmonary fibrosis. Imaging was consistent with usual interstitial pneumonia, marked by basilar and peripheral predominant reticulation, traction bronchiectasis, and honeycombing. Contemporaneous pulmonary function tests revealed a total lung capacity of 55% of predicted and a forced vital capacity of 59% of predicted. His diffusion capacity was severely reduced, and he desaturated to 91% on room air on a 6-minute walk test.
processes leading to senescent AECs, dysfunctional fibroblasts, and altered ECM can be feed-forward events, emphasizing the complicated and propagating nature of UIP.
The strong association of UIP and aging, UIP, as well as the relatively common occurrence of subclinical interstitial lung abnormalities observed in cohorts of older patients, raise the question of whether pulmonary fibrosis is a normal process of aging. 89 If so, does IPF represent the precocious onset, or a particularly aggressive form of a naturally occurring process? This remains an unanswered question. While peripheral reticulations and nonspecific cystic changes are observed on chest CT scans of some older people (Fig. 3) , honeycombing is not a normal finding with aging, and nearly always serves as a marker of a progressive disease process. 89 When interstitial changes are associated with pulmonary symptoms or impaired lung function, patients should be actively managed for ILD. Short of this, the optimal follow-up of patients with subclinical reticular disease is unclear. This is poised to become an increasingly common clinical conundrum with the expanding elderly population and the widespread utilization of chest CT imaging for a variety of screening and diagnostic purposes. Until outcomes data are available to guide management, a ! !
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However, the injury is recorded: accelerated cell turnover from damage eventually can lead to replicative senescence. B A FIGURE 2. A, The left most unit shows normal alveolar features, with a healthy population of type I AECs (elongated cells), fibroblasts (triangles) on surveillance in the extracellular matrix, and intact capillary structures (with red blood cells present in this depiction). In usual interstitial pneumonia, injury to AECs (step 1) initiates a cascade of events (step 2) culminating in the loss of type I AECs, accumulation of pathologic type II AECs, elaboration of collagen by dysfunctional fibroblasts, and destruction of capillary units. The loss of type I AECs is an incompletely understood process, although apoptosis is a contributing factor. Aging-related processes of oxidative stress and mitochondrial dysfunction are implicated in the injury response of type II AECs, which develop a hyperplastic, senescent phenotype. This phenotype conversion is driven by the DDR signaling program (B). AEC indicates alveolar epithelial cell; DDR, DNA damage response.
reasonable approach for asymptomatic patients is to obtain baseline pulmonary function testing, with several follow-up tests (every 6 to 12 mo). If pulmonary function testing is normal and remains so periodic assessment of symptoms will suffice for most patients. A low threshold for repeat imaging is prudent for patients with new and unexplained pulmonary symptoms or declining lung function values.
MANAGEMENT CONSIDERATIONS AND OUTCOMES
Optimal ILD management begins with establishing the diagnosis as precisely as possible. Ideally, when the combination of imaging and clinical features do not uphold a specific diagnosis, histopathology is indicated for further evaluation. However, for many elderly patients, real-life considerations limit pursuit of a surgical lung biopsy. Higher rates of comorbidities and decreased physiological reserve contribute to increased operative risks in the elderly. 38, 90, 91 While comorbidities are readily identified with a thorough medical history and examination, the physiological robustness of a patient is not always apparent before a major stress such as surgery is applied. Bronchoscopy with bronchoalveolar lavage serves is an alternative or complementary diagnostic procedure in some cases. In the most recent multisociety statement on IPF, bronchoscopy was not included as a recommended diagnostic procedure. 92 However, bronchoscopy is often utilized when sarcoidosis or HP are suspected. A lymphocytosis and an elevated CD4/CD8 ratio in bronchoalveolar lung fluid support, but alone do not establish a diagnosis of sarcoidosis. The latter point particularly important to consider in older patients; in a study of bronchoalveolar lung fluid from older versus younger healthy subjects, the elderly cohort had a higher percentage of lymphocytes (29% vs. 10%; P > 0.01), and a significantly higher CD4/ CD8 ratio (7.6 vs. 1.9; P > 0.01). 18 For HP, a lymphocytosis on bronchoalveolar lavage or typical findings on transbronchial biopsy support the diagnosis. Literature reports cite lymphocytosis ranges of 20% to 40% as compatible with HP. 51, 93 However, even with the lower cut-off of 20%, lymphocytosis is not a reliable finding in fibrotic HP, and lavage fluid results may be more helpful to rule in rather than rule out fibrotic HP. 50, 93 Compared to younger patients, elderly patients undergoing bronchoscopy, rates of hypoxemia, bleeding, hypotension and, among patients undergoing biopsy, pneumothorax are higher. [94] [95] [96] Yet, complication rates among the elderly still tend to be acceptable, and serious complications are infrequent when patients are appropriately selected for the procedure. Cryobiopsy is generally a safer alternative to surgical lung biopsy, although this diagnostic modality has not been specifically studied in elderly patients. 97 Treatment for ILD includes immunosuppressive therapies for CTD-ILD and other inflammatory ILDs, and antifibrotic therapies for UIP/IPF. While phase III studies of pirfenidone in IPF excluded patients older than 80, there is no age limit for currently available antifibrotic agents, and the overall condition of the patient is generally more important than age in determining who may best tolerate these medications. 98 In older patients, the potential for medication side effects is higher in general, and polypharmacy is a concern; a recent review nicely addressed polypharmacy considerations for antifibrotic medications in particular. 99, 100 This is one of several aspects of ILD care affected by age (Table 2) . For tolerance and toxicity reasons, careful follow-up is indicated for elderly patients started on systemic treatments. Yet, frequent clinic visits can be especially burdensome for the older patient. In between regular clinic visits, alternative methods of contact (phone calls, electronic communications) may facilitate close follow-up.
The upper age limit for lung transplantation has been increasing. Between 2006 and 2012, 10% of recipients were older than 65 at the time of transplant. 101 Ethical and medical considerations generally limit this option for the very elderly, but, in many North American centers, patients up to 75 years of age may be considered. 102 Transplant outcomes are generally worse in older versus younger recipients, including those with ILD. Utilizing data from the largest registry of lung transplant recipients from 1990 to 2011, the median survival for patients with underlying ILD was 3.8 years in patients older than 65, compared with 4.5 years in the combined age group. 101 While rates of bronchiolitis obliterans syndrome did not appear agerelated, rates of other long-term complications such as malignancy and significant renal dysfunction were higher among elderly recipients. In addition, caregiver assistance may be FIGURE 3. Axial image from a computed tomographic scan of an elderly man with incidentally noted interstitial lung abnormalities. Abnormalities were most prominent at the anatomic level captured in this image, and included mild subpleural peripheral reticulations without ground-glass opacities or honeycombing (A); these findings were stable from a scan performed several years before. He was free of pulmonary symptoms, and spirometry testing and oxygen measures were normal. On follow-up imaging, the interstitial abnormalities progressed slowly and minimally over 4 years (B).
limited or more burdensome for older patients, who more often have an elderly partner or live alone. That said, carefully selected older patients can do well with lung transplantation and, similar to younger cohorts, average survival has been steadily increasing for this age group.
The impact of age on mortality in ILD is not clear. In one study of patients with IPF, advanced age at the time of diagnosis was associated with a worse prognosis. 103 However, recent findings have challenged the premise that age at diagnosis is an independent predictor of idiopathic ILD related mortality. 104 Acute exacerbation is a feared complication of ILD, and is associated with low survival rates, regardless of patient age. Best described in IPF, acute exacerbations may also occur in HP and CTD-ILD when UIP is the underlying pattern. In CTD-ILD, but not in IPF, older age at the time of ILD diagnosis has been identified as a risk factor for acute exacerbations. 105, 106 Further research controlling for possible confounding variables is needed to confirm this finding. Counseling all patients with ILD, regardless of age, about this possible outcome is prudent.
CONCLUSIONS
A variety of ILDs are observed among the elderly, although UIP-pattern diseases such as IPF are the most strongly associated with aging. Epithelial cell injury, senescence of type II AECs with the SASP signaling program, and dysfunctional fibroblasts are critical events in UIP. While cellular injury is not unique to old age, several factors of aging contribute to failed wound healing, and aging seems to be a necessary although not sufficient risk factor for UIP. The number of elderly patients with CTD-ILD is growing. Enhanced clinical management of autoimmune disease has resulted in many patients living to older age, and new-onset CTD-ILD in older age is not uncommon. In addition, a sizeable minority of elderly ILD patients has fibrotic HP, often presenting without a clinically evident prodrome inflammatory phase. More research is needed to better understand this phenotype. For unclassifiable ILD, the decision to pursue surgical lung biopsy is considered in the context of age and comorbidity burden. Data to better define the safety profile of cryobiopsy in advanced age are eagerly anticipated. Declining lung function, a normal process of aging, accentuates the impact of ILD in the elderly and compromises pulmonary reserve. Polypharmacy and medication side effects are important concerns for elderly patients starting treatment for ILD. However, it should also be recognized that many older patients, including those with ILD, can readily participate in exercise or rehabilitation programs, and in other ways can maintain an acceptable quality of life, as they accommodate their disease. In addition, lung transplant can be a successful treatment option for patients up to 75 years of age. Therefore, optimal clinical care of elderly patients with ILD includes taking a thorough functionality history, soliciting input about personal preferences and goals, ensuring close follow-up when systemic medications are initiated, and maintaining vigilance for potential comorbidities. Finally, the discovery of subclinical mild interstitial abnormalities is not uncommon in older patients subjected to chest CT scanning. While generally considered benign, the long-term outcomes associated with this finding are not known and need to be evaluated to inform clinical management. 
